XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.
F
F

Fresenius


Berita

Bechtle, Schneider Electric, Sobi

EUROPE RESEARCH ROUNDUP-Bechtle, Schneider Electric, Sobi Feb 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bechtle, Schneider Electric and Sobi on Thursday. HIGHLIGHTS * Bechtle AG BC8G.DE : Berenberg raises to buy from hold; raises PT to EUR 57 from EUR 41 * Moneysupermarket.com MONY.L : Berenberg raises to buy from hold * Saab AB SAABb.ST : Citigroup cuts to neutral from buy * Schneider Electric SCHN.PA : HSBC cuts to hold
A
B
B
B
C
E
F
G
H
H
H
I
I
L
L
P
S
S
U
W
A
A
A
B
B
B
E
F
R
S
W

Fresenius rises after Q4 beat, 'conservative' guidance

BUZZ-Fresenius rises after Q4 beat, 'conservative' guidance Updates share move, adds analyst comment ** S hares in Fresenius FREG.DE rise around 4%, reversing a fall in early trade, after the German healthcare group reported Q4 operating profit beat and announced a guidance which J.P.Morgan says can be seen as "conservative" ** Fresenius reported q
F
F
G

Fresenius slips after it forecasts lower-than-expected 2024 growth

BUZZ-Fresenius slips after it forecasts lower-than-expected 2024 growth ** German healthcare group Fresenius' FREG.DE stock is down 1.7% in early trade, as it forecast lower-than-expected revenue and earnings growth this year ** Fresenius sees organic revenue growth of between 3% and 6% and EBIT growth of between 4% and 8% at constant currency ** A
F
F
G

Healthcare group Fresenius tops Q4 profit forecast, shares rise

UPDATE 2-Healthcare group Fresenius tops Q4 profit forecast, shares rise Recasts with share move, savings target By Tristan Veyet Feb 21 (Reuters) - German healthcare firm Fresenius FREG.DE beat expectations with a 13% jump in fourth-quarter operating earnings on Wednesday after it exceeded its costs savings target for 2023. CEO Michael Sen, who took the helm a year ago, has been restructuring the group to cut costs and debt after it was hit by a decline in earnings at its former dialysis unit F
F
F
G

Healthcare group Fresenius tops Q4 operating profit expectations

Healthcare group Fresenius tops Q4 operating profit expectations Feb 21 (Reuters) - Fresenius FREG.DE reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at its hospital project development unit Vamed. The diversified healthcare group reported quarterly earnings before interests and taxes, and before special items, of 634 million euros ($685 million), 7% above a
F
F

FMC shares slide as analysts focus on weaker patient volumes outlook

UPDATE 3-FMC shares slide as analysts focus on weaker patient volumes outlook Shares tank despite robust earnings, outlook Patient volumes outlook lower than peer's -analysts Few patients on GLP-1s, growth rate very slow -CEO Recasts with share move, adds analyst and CEO comments By Andrey Sychev and Chiara Holzhaeuser Feb 20 (Reuters) - Fresenius Medical Care's FMEG.DE shares fell 5% on Tuesday, despite upbeat quarterly results and higher 2024 guidance, with analysts highlighting a weak outlook
F
F
D

Dialysis firm FMC sees robust 2024 earnings growth after strong Q4

Dialysis firm FMC sees robust 2024 earnings growth after strong Q4 Feb 20 (Reuters) - Fresenius Medical Care FMEG.DE on Tuesday said it expects its core earnings to grow by a mid- to high-teens percentage this year, after the German dialysis specialist's fourth-quarter earnings topped market expectations. FMC, which employs 128,000 people in 4,000 clinics globally, said its adjusted operating income grew 18% to 555 million euros ($598 million) in the October-December period, compared with a medi
F
F

Preparing for trade tensions

LIVE MARKETS-Preparing for trade tensions STOXX 600 down 0.1% China stocks see modest gains Takeover battle for Currys heats up NYSE shut for holiday Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com PREPARING FOR TRADE TENSIONS Trade tensions will most likely return to the fore should Donald Trump win the U.S.
A
B
B
B
C
F
I
K
L
N
N
R
S
S
S
T
V
A
A
S
F
U
G

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead Feb 16 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 21-Feb-2024 BMO FREG.DE Fresenius SE & Co KGaA Q4 2023 Fresenius SE & Co KGaA Earnings Release 22-Feb-2024 BMO MBGn.DE Mercedes Benz Group AG Q4 2023 Mercedes Benz Group AG Earnings Release 22-Feb-2024 BMO HEIG.DE Heidelberg Materials AG Full Year 2023 Heidelberg Materials AG Earnings Release 23-Feb-
B
D
F
I
A
G

Fresenius´ Majority Owned mAbxience Announces CDMO Agreement With Biosidus For Treatment Of Fabry Disease

BRIEF-Fresenius´ Majority Owned mAbxience Announces CDMO Agreement With Biosidus For Treatment Of Fabry Disease Feb 5 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : MABXIENCE ANNOUNCES CDMO AGREEMENT WITH BIOSIDUS FOR TREATMENT OF FABRY DISEASE MABXIENCE, A FRESENIUS KABI MAJORITY-OWNED GROUP, TODAY ANNOUNCED A CDMO AGREEMENT WITH BIOSIDUS FOR THE M
F

Fresenius Completes Divestment Of Fertility Services Group Eugin

BRIEF-Fresenius Completes Divestment Of Fertility Services Group Eugin Jan 31 (Reuters) - Fresenius SE & Co KGaA FREG.DE : SUCCESSFULLY COMPLETES DIVESTMENT OF FERTILITY SERVICES GROUP EUGIN Further company coverage: FREG.DE (Gdansk Newsroom)
F

Fresenius Kabi Launches Generic Drug For Treatment Of Serious Fungal Infections In U.S.

BRIEF-Fresenius Kabi Launches Generic Drug For Treatment Of Serious Fungal Infections In U.S. Jan 29 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : FRESENIUS KABI LAUNCHES GENERIC DRUG FOR THE TREATMENT OF SERIOUS FUNGAL INFECTIONS IN THE U.S. Further company coverage: FREG.DE (Gdansk Newsroom)
F

Admiral Group, Endesa, Wizz Air

EUROPE RESEARCH ROUNDUP-Admiral Group, Endesa, Wizz Air Jan 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Admiral Group, Endesa, and Wizz Air, on Monday. HIGHLIGHTS * Admiral Group Plc ADML.L : HSBC raises target price to 2500p from 2200p * Boliden AB BOL.ST : Bernstein cuts to market-perform from outperform * CMC Markets Plc CMCX.L : Peel Hunt raises to buy from add * Endesa ELE.MC : Goldman Sachs raises to buy from neutral * W
A
A
A
B
B
B
B
B
B
B
B
C
C
C
C
C
D
E
E
E
F
F
H
J
L
N
P
R
R
S
S
A
A
A
A
D
D
D
E
F
R
T

Fresenius Kabi Majority-Owned Group mAbxience Announced A Strategic Licensing Agreement With Intas Pharmaceuticals Ltd

BRIEF-Fresenius Kabi Majority-Owned Group mAbxience Announced A Strategic Licensing Agreement With Intas Pharmaceuticals Ltd Dec 20 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : MABXIENCE ANNOUNCES LICENSING AGREEMENT WITH INTAS FOR ETANERCEPT BIOSIMILAR UNDER AGREEMENT, MABXIENCE WILL DEVELOP, MANUFACTURE, AND SUPPLY ETANERCEPT BIOSIMILAR FROM ITS
F

Fresenius SE Fresenius Kabi Enters Into Multiyear Supply And Service Agreement For Its Ivenix Infusion System

BRIEF-Fresenius SE Fresenius Kabi Enters Into Multiyear Supply And Service Agreement For Its Ivenix Infusion System Dec 14 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : FRESENIUS KABI ENTERS INTO MULTIYEAR SUPPLY AND SERVICE AGREEMENT FOR ITS IVENIX INFUSION SYSTEM Further company coverage: FREG.DE (Gdansk Newsroom)
F

Fresenius plans to sell rehabilitation care clinics - FAZ

Fresenius plans to sell rehabilitation care clinics - FAZ FRANKFURT, Dec 8 (Reuters) - Fresenius FREG.DE has hired UBS UBSG.S to manage the sale of its rehabilitation care clinic business as the German healthcare group focuses on core activities, Frankfurter Allgemeine Zeitung reported on Friday, citing financial sources. The rehabilitation clinics, also known as post-acute care clinics and part of the group's hospital project development business Vamed, could be worth as much as 800 million eur
F
U
F

Fresenius slides as it suspends dividend

BUZZ-Fresenius slides as it suspends dividend ** Shares in Fresenius FREG.DE slip 3% in early Frankfurt trade after the German healthcare group said it would cancel its dividend and bonuses for the year in order to retain state aid ** The company said the decision would contribute to its "sustainable development and value enhancement" by reducing debt as a multiple of operating income by 20 to 25 basis points.
F
G

Fresenius cancels 2023 dividend, bonuses to retain state aid

UPDATE 1-Fresenius cancels 2023 dividend, bonuses to retain state aid Adds details on rationale in paragraph 3, background from paragraph 3 By Ludwig Burger FRANKFURT, Dec 5 (Reuters) - German healthcare group Fresenius FREG.DE said on Tuesday it would not be allowed to make dividend and management bonus payments for 2023 because it decided to keep state aid it received to reduce high energy costs at its hospitals business.
F
F

Fresenius will not pay dividend, bonuses for 2023 to salvage state aid

Fresenius will not pay dividend, bonuses for 2023 to salvage state aid FRANKFURT, Dec 5 (Reuters) - German healthcare group Fresenius FREG.DE on Tuesday said it would not be allowed to make dividend and management bonus payments for 2023 because it decided to keep state aid it received to help offset high energy costs at its hospitals business. Rep
F

Auction Technology Group, Euroapi SA, Land Securities

EUROPE RESEARCH ROUNDUP-Auction Technology Group, Euroapi SA, Land Securities Dec 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Auction Technology Group, Euroapi SA and Land Securities, on Tuesday. HIGHLIGHTS * Auction Technology Group Plc ATG.L : Barclays cuts to equal-weight from overweight * Euroapi SA EAPI.PA : JP Morgan cuts to neutral from overweight * Land Securities LAND.L : Goldman Sachs raises to buy from neutral * Sa
A
A
B
C
C
C
C
C
C
C
D
E
F
F
G
G
G
I
P
A
B
L



Syarat

Aset Popular

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang menggunakan leverage mungkin tidak sesuai untuk semua individu. Sila lihat Pendedahan Risiko kami.